Technical Data
G8951-26T
Granulocyte Macrophage Colony Stimulating Factor, Recombinant, Human (GM-CSF, GMCSF, Colony-stimulating Factor, CSF, Colony Stimulating Factor 2 (Granulocyte-macrophage), CSF2, MGC131935, MGC138897, Molgramostin, Sargramostim)
10ug
Molecular Biology Storage: -20CShipping: Blue Ice
Source:
Recombinant corresponding to 127aa of human Granulocyte Macrophage-Colony Stimulating Factor expressed in E.coli is a single, non-glycosylated, polypeptide chain.

Molecular Weight:
~14.5kD

Biological Activity:
The ED50 as determined by the dose-dependent stimulation of the proliferation of human TF-1 cells (human erythroleukemic indicator cell line) is less then 0.1ng/ml, corresponding to a Specific Activity of 11.1x10 6IU/mg.

Dimers and Aggregates:
1% (SDS-PAGE)

Protein Content:
Protein quantitation was carried out by two independent methods: 1.UV spectroscopy at 280nm using the absorbency value of 0.963 as the extinctioncoefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of GM-CSF as a Reference Standard.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
~14.5kD
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug)
Concentration: Not determined
Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Adenosine potentiates stimulatory effects on granulocyte-macrophage hematopoietic progenitor cells in vitro of interleukin-3 and stem cell factor, but not those of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and interleukin-11. Physiol Res 2005 Dec 12; 2. Acute CD4+ T lymphocyte-dependent interleukin-1-driven arthritis selectively requires interleukin-2 and interleukin-4, joint macrophages, granulocyte-macrophage colony-stimulating factor, interleukin-6, and leukemia inhibitory factor. Arthritis Rheum 2005 Dec;52(12):3749-3754. 3. Granulocyte-macrophage colony-stimulating factor as an arteriogenic factor in the treatment of ischaemic stroke. Expert Opin Biol Ther 2005 Dec;5(12):1547-56. 4. [The pulmonary expression of granulocyte-macrophage colony-stimulating factor and surfactant protein in adult idiopathic pulmonary alveolar proteinosis.]. Zhonghua Nei Ke Za Zhi 2005 Nov;44(11):832-5. 5. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. J Virol 2005 Dec;79(24):15043-53. 6. Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: a placebo controlled randomized study in healthy subjects. Eur J Med Res 2005 Oct 18;10(10):411-8.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.